Cargando…

Prevalence of ESR1 Mutation in Chinese ER-Positive Breast Cancer

BACKGROUND: ESR1 mutation and its possible relation to endocrine therapy resistance in ER-positive breast cancers have been studied with respect to genetic sequencing data from Western patients but rarely from Chinese patients. This study aimed to investigate the prevalence of ESR1 mutation in Chine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Wenzhen, Ren, Chongyang, Wang, Yulei, Wen, Lingzhu, Zhang, Guochun, Liao, Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982432/ https://www.ncbi.nlm.nih.gov/pubmed/32021303 http://dx.doi.org/10.2147/OTT.S233662

Ejemplares similares

GSTM1 polymorphism in Oncotype DX assay is a potential predictive factor for taxane-based neoadjuvant chemotherapy in estrogen receptor-positive Chinese breast cancer patients
por: Zhang, Guochun, et al.
Publicado: (2019)

Characterization of AKT Somatic Mutations in Chinese Breast Cancer Patients
por: Wen, Lingzhu, et al.
Publicado: (2021)

Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy
por: Li, Kai, et al.
Publicado: (2020)

Spectrum of MAP3K1 mutations in breast cancer is luminal subtype-predominant and related to prognosis
por: Li, Cheukfai, et al.
Publicado: (2022)

PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing
por: Jia, Minghan, et al.
Publicado: (2021)

Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer
por: Xiao, Weikai, et al.
Publicado: (2021)

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
por: Spoerke, Jill M., et al.
Publicado: (2016)

Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer
por: Chen, Bo, et al.
Publicado: (2020)

Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status
por: Zhang, Guochun, et al.
Publicado: (2022)

Genomic alteration profile and PD‐L1 expression among different breast cancer subtypes in Chinese population and their correlations
por: Li, Kai, et al.
Publicado: (2022)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

Heterogenous and Low Expression of HER2 in Breast Cancer Overcome by DS-8201a in a Heavily Treated Patient: Case Report and Review of the Literature
por: Li, Cheukfai, et al.
Publicado: (2022)

Identification of a novel microRNA recurrence-related signature and risk stratification system in breast cancer
por: Lai, Jianguo, et al.
Publicado: (2019)

ESR1 mutations in breast cancer
por: Clatot, Florian, et al.
Publicado: (2017)

Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients
por: Takeshita, Takashi, et al.
Publicado: (2017)

Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

Prevalence of Estrogen Receptor Alpha (ESR1) Somatic Mutations in Breast Cancer
por: Kinslow, Connor J, et al.
Publicado: (2022)

CircPVT1 promotes ER‐positive breast tumorigenesis and drug resistance by targeting ESR1 and MAVS
por: Yi, Jia, et al.
Publicado: (2023)

Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer
por: Bos, M. K., et al.
Publicado: (2023)

microRNA-Dependent Modulation of Genes Contributes to ESR1's Effect on ERα Positive Breast Cancer
por: Gao, Shan, et al.
Publicado: (2020)

Comprehensive analysis of autophagy‐related prognostic genes in breast cancer
por: Lai, Jianguo, et al.
Publicado: (2020)

Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer
por: Reinert, Tomas, et al.
Publicado: (2017)

ESR/ERS white paper on lung cancer screening
por: Kauczor, Hans-Ulrich, et al.
Publicado: (2015)

ESR/ERS white paper on lung cancer screening
por: Kauczor, Hans-Ulrich, et al.
Publicado: (2015)

Author Correction: Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

ESR1 Gene Mutations and Liquid Biopsy in ER-Positive Breast Cancers: A Small Step Forward, a Giant Leap for Personalization of Endocrine Therapy?
por: Betz, Margaux, et al.
Publicado: (2023)

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
por: Brett, Jamie O., et al.
Publicado: (2021)

Experiments with relativistic exotic nuclei at the ERS - ESR facilities
por: Geissel, H
Publicado: (1996)

Detection of ESR1 Mutations Based on Liquid Biopsy in Estrogen Receptor-Positive Metastatic Breast Cancer: Clinical Impacts and Prospects
por: Liao, Hao, et al.
Publicado: (2020)

ESR1 mutations in metastatic lobular breast cancer patients
por: Desmedt, Christine, et al.
Publicado: (2019)

Influence of Estrogen Treatment on ESR1(+) and ESR1(−) Cells in ER(+) Breast Cancer: Insights from Single-Cell Analysis of Patient-Derived Xenograft Models
por: Mori, Hitomi, et al.
Publicado: (2021)

Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer
por: Takeshita, Takashi, et al.
Publicado: (2018)

ESR position paper on ultrasound
Publicado: (2010)

Investigation of Estrogen Receptor (ESR1) for Breast Cancer from Traditional Chinese Medicine
por: Hung, Tzu-Chieh, et al.
Publicado: (2014)

ESR1 Mutation Detection and Dynamics in Meningeal Carcinomatosis in Breast Cancer
por: Carausu, Marcela, et al.
Publicado: (2019)

ESR1 alterations and metastasis in estrogen receptor positive breast cancer
por: Lei, Jonathan T., et al.
Publicado: (2019)

Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics
por: Xiao, Weikai, et al.
Publicado: (2021)

Selenium-binding protein 1 transcriptionally activates p21 expression via p53-independent mechanism and its frequent reduction associates with poor prognosis in bladder cancer
por: Wang, Yulei, et al.
Publicado: (2020)

Concomitant PIK3CA and TP53 Mutations in Breast Cancer: An Analysis of Clinicopathologic and Mutational Features, Neoadjuvant Therapeutic Response, and Prognosis
por: Lin, Xiao-Yi, et al.
Publicado: (2023)

ESR1 ligand binding domain mutations in hormone-resistant breast cancer
por: Toy, Weiyi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_qc7ra9q9cladcr8jse1gjmplht